🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Breast Cancer Brain Metastases

Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer NCT06072807Phase 41 site📍 New York Weill Medical College of Cornell University · Tests: Brain Imaging with 18F-FES Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases NCT05866432Phase 21 site📍 Vienna Medical University of Vienna · Tests: Datopotamab deruxtecan DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs NCT06176261Phase 23 sites📍 Miami📍 Boston📍 Durham Nancy Lin, MD · Tests: Datopotamab Deruxtecan Asciminib in HER2+ Breast Cancer Brain Metastases NCT07136428Phase 1, Phase 21 site📍 Durham Duke University · Tests: Asciminib and Trastuzumab A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors NCT07361562Phase 115 sites📍 Scottsdale📍 Scottsdale📍 New Haven Cogent Biosciences, Inc. · Tests: CGT4255 A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases NCT06764940Phase 212 sites📍 Duarte📍 Los Angeles📍 San Diego Biostar Pharma, Inc. · Tests: Utidelone, Utidelone in combination with capecitabine, Utidelone in combination with capecitabine, Utidelone in combina… Cancer Genetic Testing in Ethnic Populations NCT04475640NA2 sites📍 Scottsdale📍 Jacksonville Mayo Clinic · Tests: Biospecimen Collection, Genetic Testing MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer NCT06247449NA1 site📍 Toronto Sunnybrook Health Sciences Centre · Tests: Brain imaging, Analysis of circulating tumor DNA, Testing Morbidities Index Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer NCT07117864NA1 site📍 Beijing QIAO LI · Tests: T-DXd concurrent brain radiotherapy A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis. NCT06839547n/a1 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Radiotherapy + Novel Anti-tumor Drug Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling NCT04965064Phase 21 site📍 Rochester University of Rochester · Tests: Capecitabine and Neratinib. The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study NCT04075305n/a18 sites📍 Pittsburgh📍 Houston📍 Milwaukee UMC Utrecht · Tests: Radiation therapy Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study NCT07251868n/a1 site📍 Beijing Peking University Cancer Hospital & Institute · Tests: Sacituzumab Govitecan (SG) Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases NCT05769010Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: SHR-A1811, Pyrotinib, Bevacizumab, Adebelizumab An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis NCT05376878Phase 41 site📍 Duarte City of Hope Medical Center · Tests: Copper Cu 64-DOTA-Trastuzumab, Magnetic Resonance Imaging, Positron Emission Tomography, Trastuzumab, Trastuzumab Derux… A Phase IIa Study to Evaluate NBQ72S NCT06810804Phase 21 site📍 Beijing Nantong Bencao Quadriga Medical Technology Co. Ltd. · Tests: NBQ72S Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis NCT06718933Phase 1, Phase 21 site📍 Shanghai Fudan University · Tests: SHR-A1811, Bevacizumab, Pyrotinib SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases NCT04923542Phase 1, Phase 22 sites📍 Tampa📍 Columbus H. Lee Moffitt Cancer Center and Research Institute · Tests: Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases NCT05535413Phase 1, Phase 21 site📍 Changsha Hunan Cancer Hospital · Tests: UTD1 combined with capecitabine Sensitivity of Organoids to Predict Treatment Outcome in Breast Cancer Metastases NCT06468124n/a2 sites📍 London📍 London King's College London Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer NCT04348747Phase 23 sites📍 Tampa📍 Buffalo📍 Charlottesville Roswell Park Cancer Institute · Tests: Anti-HER2/HER3 Dendritic Cell Vaccine, Pembrolizumab Brain Metastasis Development Mechanism in BCBM Patients NCT06330870NA1 site📍 Seoul Samsung Medical Center · Tests: WGS/TME evaluation Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients NCT03449238Phase 1, Phase 23 sites📍 New York📍 New York📍 New York Weill Medical College of Cornell University · Tests: Pembrolizumab Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM. NCT07638852Phase 21 site📍 Shanghai Fudan University · Tests: Radiation Therapy, Adebelimab, Bevacizumab, Cisplatin or carboplatin RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive NCT07413939Phase 2, Phase 3206 sites📍 Huntsville📍 Gilbert📍 San Francisco Hoffmann-La Roche · Tests: RO7771950, Tucatinib, Trastuzumab, Capecitabine Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer NCT05386108Phase 1, Phase 286 sites📍 Fullerton📍 Los Angeles📍 Urbana Stemline Therapeutics, Inc. · Tests: Elacestrant, Abemaciclib Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection NCT07383649Phase 21 site📍 Houston The Methodist Hospital Research Institute · Tests: Valganciclovir Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases NCT04899908Phase 22 sites📍 Boston📍 Boston Brigham and Women's Hospital · Tests: Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis NCT06839560Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Adebrelimab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy, Adebrelimab+VEX Metronomic Chemotherapy+Delayed Radiot… A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC NCT06598046Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: Utidelone and capecitabine
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy